320 related articles for article (PubMed ID: 18838631)
1. Effects of second-generation antipsychotic medication on smooth pursuit performance in antipsychotic-naive schizophrenia.
Lencer R; Sprenger A; Harris MS; Reilly JL; Keshavan MS; Sweeney JA
Arch Gen Psychiatry; 2008 Oct; 65(10):1146-54. PubMed ID: 18838631
[TBL] [Abstract][Full Text] [Related]
2. Sensorimotor transformation deficits for smooth pursuit in first-episode affective psychoses and schizophrenia.
Lencer R; Reilly JL; Harris MS; Sprenger A; Keshavan MS; Sweeney JA
Biol Psychiatry; 2010 Feb; 67(3):217-23. PubMed ID: 19782964
[TBL] [Abstract][Full Text] [Related]
3. Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia.
Hutton SB; Crawford TJ; Gibbins H; Cuthbert I; Barnes TR; Kennard C; Joyce EM
Psychopharmacology (Berl); 2001 Sep; 157(3):284-91. PubMed ID: 11605084
[TBL] [Abstract][Full Text] [Related]
4. Effect of typical antipsychotic medications and clozapine on smooth pursuit performance in patients with schizophrenia.
Friedman L; Jesberger JA; Meltzer HY
Psychiatry Res; 1992 Jan; 41(1):25-36. PubMed ID: 1348583
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
7. Smooth pursuit and saccadic abnormalities in first-episode schizophrenia.
Hutton SB; Crawford TJ; Puri BK; Duncan LJ; Chapman M; Kennard C; Barnes TR; Joyce EM
Psychol Med; 1998 May; 28(3):685-92. PubMed ID: 9626724
[TBL] [Abstract][Full Text] [Related]
8. Effects of risperidone on procedural learning in antipsychotic-naive first-episode schizophrenia.
Harris MS; Wiseman CL; Reilly JL; Keshavan MS; Sweeney JA
Neuropsychopharmacology; 2009 Jan; 34(2):468-76. PubMed ID: 18536701
[TBL] [Abstract][Full Text] [Related]
9. Reduced attentional engagement contributes to deficits in prefrontal inhibitory control in schizophrenia.
Reilly JL; Harris MS; Khine TT; Keshavan MS; Sweeney JA
Biol Psychiatry; 2008 Apr; 63(8):776-83. PubMed ID: 18191110
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels.
Garyfallos G; Dimelis D; Kouniakis P; Sidiropoulos N; Karastergiou A; Lavrentiadis G; Giouzepas J; Fokas K
Eur Psychiatry; 2003 Oct; 18(6):320-1. PubMed ID: 14611929
[No Abstract] [Full Text] [Related]
11. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
12. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
13. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia.
Reilly JL; Harris MS; Keshavan MS; Sweeney JA
Arch Gen Psychiatry; 2006 Nov; 63(11):1189-97. PubMed ID: 17088499
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment effects on eye movement control.
Reilly JL; Lencer R; Bishop JR; Keedy S; Sweeney JA
Brain Cogn; 2008 Dec; 68(3):415-35. PubMed ID: 19028266
[TBL] [Abstract][Full Text] [Related]
15. Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.
Frazier JA; Giuliano AJ; Johnson JL; Yakutis L; Youngstrom EA; Breiger D; Sikich L; Findling RL; McClellan J; Hamer RM; Vitiello B; Lieberman JA; Hooper SR
J Am Acad Child Adolesc Psychiatry; 2012 May; 51(5):496-505. PubMed ID: 22525956
[TBL] [Abstract][Full Text] [Related]
16. Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.
Ayesa-Arriola R; Rodríguez-Sánchez JM; Pérez-Iglesias R; Roiz-Santiáñez R; Martínez-García O; Sánchez-Moreno J; Tabarés-Seisdedos R; Vázquez-Barquero JL; Crespo-Facorro B
Psychopharmacology (Berl); 2013 Jun; 227(4):615-25. PubMed ID: 23455591
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
[TBL] [Abstract][Full Text] [Related]
18. The effect of change in clinical state on eye movement dysfunction in schizophrenia.
Kallimani D; Theleritis C; Evdokimidis I; Stefanis NC; Chatzimanolis I; Smyrnis N
Eur Psychiatry; 2009 Jan; 24(1):17-26. PubMed ID: 18922684
[TBL] [Abstract][Full Text] [Related]
19. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
20. The heterogeneity of antipsychotic response in the treatment of schizophrenia.
Case M; Stauffer VL; Ascher-Svanum H; Conley R; Kapur S; Kane JM; Kollack-Walker S; Jacob J; Kinon BJ
Psychol Med; 2011 Jun; 41(6):1291-300. PubMed ID: 20925971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
